University  |   Hospital  |   Pulse  |   JeffNet   |   RAP   Remote Access Portal
Find People  |   JeffMail  |   JeffCal  |   JeffShare  

TJU | JMC logo
The Bottom Line: Achieving Diabetes Treatment Goals
VOLUME 1 ISSUE 1
CASE KM
VOLUME 1 ISSUE 2
CASE WM
CASE WM
EDITORS
CME INFORMATION
DISCLAIMER
REFERENCES
VOLUME 1 ISSUE 3
CASE SW
VOLUME 1 ISSUE 4
CASE JJ
VOLUME 1 ISSUE 5
CASE PD
VOLUME 1 ISSUE 6
CASE MP


REFERENCES

VOLUME 1 ISSUE 2 CASE WM

  1. Robins SJ, Collins D, Fye CL, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.

  2. American Diabetes Association. Management of Dyslipidemia in Adults With Diabetes. Diabetes Care. 2003;26:S83–S86.

  3. National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III). Executive Summary. NIH Publication 01–3670, May 2001. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/

  4. Avandia® (rosiglitazone) prescribing information. GlaxoSmithKline. Research Triangle, NC, March 2003.

  5. Actos® (pioglitazone) prescribing information. Takeda Pharmaceuticals America Inc. Lincolnshire, IL, July 2002.

  6. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947–952.

  7. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocrine Practice. 2002;8:406–410.

  8. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther. 2002;4:145–151.

  9. Gupta EL, Ito MK. Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Heart Dis. 2002;4:399–409.

  10. Koda-Kimble MA, Carlisle BA. Diabetes mellitus. In: Koda- Kimble MA, Young LY, eds. Applied Therapeutics: The Clinical Use of Drugs. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:48.1–48.92.

  11. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567–572.

  12. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol. 2001;13:415–40.

  13. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690.

  14. Elam MB, Hunninghake DB, Davis KB, et al, for the ADMIT investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: A randomized trial. JAMA. 2000;284:1263–1270.

THIS ACTIVITY IS SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM
JOINTLY SPONSORED BY  |  TJU | JMC logo  |  BIOCENTRIC INC logo


The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.

Return to Thomas Jefferson University Home Page